C.Q. Pharmaceutical Holding Co., Ltd. (SHE:000950)

SHE:000950 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	81,242	80,255	78,185	67,657	62,354	45,104
Other Revenue	307.01	307.01	212.62	171.83	166.87	115.37
Revenue	81,549	80,562	78,397	67,829	62,521	45,220
Revenue Growth (YoY)	4.01%	2.76%	15.58%	8.49%	38.26%	33.61%
Cost of Revenue	75,665	74,641	72,162	62,038	56,817	41,012
Gross Profit	5,884	5,921	6,235	5,791	5,703	4,207
Selling, General & Admin	3,870	3,967	3,678	3,298	3,078	2,218
Research & Development	0.23	0.32	0.38	3.24	10.04	2.67
Other Operating Expenses	199.52	189.22	212.55	188.63	155.73	123.62
Operating Expenses	4,655	4,688	4,279	3,614	3,526	2,446
Operating Income	1,229	1,232	1,957	2,177	2,177	1,762
Interest Expense	-1,053	-1,138	-1,340	-1,123	-1,106	-675.52
Interest & Investment Income	449.98	488.19	393.27	355.29	347.92	325.03
Currency Exchange Gain (Loss)	-0.17	-0.17	0.18	0.44	-0.1	0.43
Other Non Operating Income (Expenses)	-40.15	-41.03	-103.03	-12.36	3.66	-104.4
EBT Excluding Unusual Items	586.26	541.54	906.96	1,397	1,423	1,307
Impairment of Goodwill	-40.22	-40.22	-20.48	-27.91	-10.32	-14.68
Gain (Loss) on Sale of Investments	-3.56	6.92	16.16	2.32	126.88	17.45
Gain (Loss) on Sale of Assets	9.99	10.53	0.79	10.05	3.52	21.54
Asset Writedown	-2.22	0.01	-0.01	-0.02	-0.35	-
Other Unusual Items	43.85	38.73	62.91	91.25	37.35	42.89
Pretax Income	594.1	557.51	966.33	1,472	1,580	1,374
Income Tax Expense	154.57	155.72	236.04	309.5	289.61	227.07
Earnings From Continuing Operations	439.53	401.79	730.29	1,163	1,291	1,147
Net Income to Company	439.53	401.79	730.29	1,163	1,291	1,147
Minority Interest in Earnings	-134.27	-118.8	-105.65	-210.72	-285.23	-263.05
Net Income	305.27	282.99	624.63	952.28	1,005	884.34
Net Income to Common	305.27	282.99	624.63	952.28	1,005	884.34
Net Income Growth	-45.64%	-54.69%	-34.41%	-5.29%	13.69%	12.22%
Shares Outstanding (Basic)	1,787	1,769	1,735	1,731	1,734	1,728
Shares Outstanding (Diluted)	1,787	1,769	1,735	1,731	1,734	1,728
Shares Change (YoY)	2.17%	1.94%	0.21%	-0.12%	0.31%	-
EPS (Basic)	0.17	0.16	0.36	0.55	0.58	0.51
EPS (Diluted)	0.17	0.16	0.36	0.55	0.58	0.51
EPS Growth	-46.79%	-55.56%	-34.54%	-5.17%	13.73%	11.85%
Free Cash Flow	517.13	-437.27	264.13	17.76	-239.38	253.82
Free Cash Flow Per Share	0.29	-0.25	0.15	0.01	-0.14	0.15
Dividend Per Share	0.060	0.060	0.050	0.060	0.105	-
Dividend Growth	20.00%	20.00%	-16.67%	-42.86%	-	-
Gross Margin	7.22%	7.35%	7.95%	8.54%	9.12%	9.30%
Operating Margin	1.51%	1.53%	2.50%	3.21%	3.48%	3.90%
Profit Margin	0.37%	0.35%	0.80%	1.40%	1.61%	1.96%
Free Cash Flow Margin	0.63%	-0.54%	0.34%	0.03%	-0.38%	0.56%
EBITDA	1,476	1,479	2,203	2,408	2,346	1,886
EBITDA Margin	1.81%	1.84%	2.81%	3.55%	3.75%	4.17%
D&A For EBITDA	246.53	246.6	246.87	231.17	169.06	124.75
EBIT	1,229	1,232	1,957	2,177	2,177	1,762
EBIT Margin	1.51%	1.53%	2.50%	3.21%	3.48%	3.90%
Effective Tax Rate	26.02%	27.93%	24.43%	21.02%	18.33%	16.52%
Revenue as Reported	81,549	80,562	78,397	67,829	62,521	45,220
Advertising Expenses	-	9.42	9.57	20.39	23.49	14.21

Source: S&P Global Market Intelligence. Standard template. Financial Sources.